CINC Overview
Upcoming Projects (CINC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CINC)
-
A third look: Discussing the potential of Baxdrostat(CIN-107) in resistant hypertension in light of the recent top line results from the Phase 2 HALO trial.
Ticker: CINC
Executed On: Dec 20, 2022 at 11:30 AM EST -
A second look: Discussing the potential of Baxdrostat(CIN-107) in resistant hypertension in light of the recent top line results from the Phase 2 HALO trial.
Ticker: CINC
Executed On: Dec 09, 2022 at 09:00 AM EST -
Discussing the potential of Baxdrostat(CIN-107) in resistant hypertension in light of the recent top line results from the Phase 2 HALO trial.
Ticker: CINC
Executed On: Dec 08, 2022 at 11:00 AM EST -
A Cardiologist's View on the developing treatment landscape for resistant hypertension and the potential of Baxdrostat(CIN-107).
Ticker: CINC
Executed On: Aug 12, 2022 at 12:00 PM EDT -
A third look at the developing treatment landscape for resistant hypertension and the potential of Baxdrostat(CIN-107)
Ticker: CINC
Executed On: Aug 12, 2022 at 10:00 AM EDT -
A second look at the developing treatment landscape for resistant hypertension, including Baxdrostat and Ocedurenone
Tickers: CINC, KBP Biosciences
Executed On: Aug 03, 2022 at 10:00 AM EDT -
A look at the developing treatment landscape for resistant hypertension, including Baxdrostat and Ocedurenone
Tickers: CINC, KBP Biosciences
Executed On: Jul 26, 2022 at 04:00 PM EDT -
A second look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Tickers: IDRSF, CINC, AZN, KBP Biosciences
Executed On: Jul 06, 2022 at 01:30 PM EDT
Upcoming & Overdue Catalysts (CINC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CINC)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
